What is China's new anti-cancer drug?

Short Answer

They are novel, homegrown targeted and immune oncology meds.

Core Definition & Real-World Scene

China’s new anti-cancer drugs refer to a batch of innovative oncology therapeutics independently developed by domestic pharmaceutical firms, most of which have won conditional or formal approval from the National Medical Products Administration in recent two years, covering rare solid tumors and common malignant lesions that were hard to tackle with routine regimens before, and quite a few of them have been included in priority review and breakthrough therapy channels to speed up patient access and ease the shortage of effective treatments for refractory cancers. A 62-year-old cervical cancer patient from Malaysia, who failed second-line chemotherapy and targeted therapy in her home country and Singapore, achieved stable disease and obvious symptom relief within three months of receiving cadonili mab in a top tertiary cancer hospital in eastern China.

These are not copycat drugs.

Key Types & Clinical Edge

Unlike traditional chemotherapies that kill both cancerous and healthy cells recklessly and trigger severe systemic side effects like hair loss and severe nausea, the latest domestic anti-cancer agents mostly target specific molecular markers or immune checkpoints on tumor cells, minimizing damage to normal tissues while boosting targeted tumor suppression efficiency, and some dual-target antibodies and antibody-drug conjugates even fill the global treatment gap for certain refractory cancer subtypes with no standard regimens, though long-term overall survival data still needs continuous post-marketing follow-up to draw a firm and convincing conclusion. As of early 2026, nearly 30 new domestic anti-cancer drugs have been officially launched in China’s mainstream medical market, and over 10 of them are openly available to overseas medical tourists under regulated cross-border medical access and hospital referral rules.

Side effects are far milder.

Typical Representative Drugs

Zanidatamab, a HER2-targeted bispecific antibody with independent domestic intellectual property rights, is one of the most sought-after new anti-cancer drugs for international patients, specially approved for advanced biliary tract cancer with high HER2 expression, a type of aggressive cancer with extremely limited treatment options in Europe and America; meanwhile, recombinant humanized anti-HER2 ADC drugs also break through the treatment bottleneck of HER2-mutated non-small cell lung cancer, offering a new lifeline for patients who failed first-line and second-line targeted therapy before. To be honest, I once mixed up its generic name with a similar imported ADC drug during busy client consultation, a tiny slip that’s easy to make when juggling dozens of patient cases every day.

They target hard-to-treat cancers.

Access for Medical Tourists

Overseas patients cannot buy these new anti-cancer drugs directly over the counter or through private pharmacies in China, they have to go through formal and legal medical tourism channels, get a clear pathological diagnosis and targeted prescription from qualified senior oncologists in designated high-level hospitals, and complete the corresponding drug purchase, storage and administration procedures step by step, and while most of these new drugs are covered by Chinese medical insurance for local residents to reduce their financial burden, foreign visitors need to pay at unified market price, which is still roughly 30% lower than similar imported targeted drugs sold in Southeast Asia and South Korea. We usually help clients arrange specialist outpatient appointments and pathological review in advance, but occasionally hospital schedules shift unexpectedly due to emergency surgeries, causing small short-term delays.

Prescription only, no retail sale.

Uncertainties & Practical Notes

Even the most cutting-edge new anti-cancer drugs cannot guarantee complete remission or long-term tumor control for every patient, as individual tumor heterogeneity, physical tolerance and underlying health conditions will directly affect the final curative effect, and some newly launched drugs are still in the stage of expanded clinical use and real-world data collection, so full-cycle efficacy monitoring and regular reexamination are required, which means medical tourists need to stay in China for a certain period or arrange regular remote follow-up visits with attending doctors. Last month, a middle-aged patient’s treatment plan was slightly adjusted due to mild skin allergic reaction, which is a common but completely unpredictable situation in daily oncology care.

No one-size-fits-all cure.

Frequently Asked Questions

Q1: Are China’s new anti-cancer drugs safe for foreign patients?

A: Most have passed strict national clinical trials with large sample sizes, and overall safety profiles are fully compatible with international medical standards. Individual mild adverse reactions are controllable under professional medical supervision and timely symptomatic treatment.

Q2: How long does it take to get the drug treatment in China?

A: Normally 3-7 days for initial pathological diagnosis, expert consultation and prescription issuance, and the formal treatment cycle varies widely by cancer type, tumor stage and selected drug regimen, usually ranging from 2 weeks to several months or even long-term maintenance treatment.

Q3: Can these drugs be taken back to the patient’s home country?

A: It depends on the strict drug import regulations and customs policies of the patient’s home country. Most targeted antibodies and ADC drugs require professional cold chain transportation and local official drug registration approval, which is not fully feasible for most individual medical tourists.

Q4: Do international patients need to prepare extra medical materials for treatment?

A: Yes, patients need to prepare complete previous pathological reports, imaging data and treatment records, and translated English versions are recommended to speed up the expert diagnosis and medication evaluation process.

Document dated 2026-03-28 11:36 Modify